Effect of Probiotics on Mycoplasma Pneumoniae Pneumonia

Effect of Probiotic WecProB on the Course of Mycoplasma Pneumoniae Pneumonia in Children

To evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with mycoplasma pneumoniae pneumonia, in comparison with placebo.

Inclusion Criteria:

1. diagnosis of MPP based on typical clinical manifestations (e.g., fever, cough, abnormal pulmonary auscultation), radiographic evidence of pneumonia on chest imaging, and laboratory findings in accordance with current pediatric community-acquired pneumonia guidelines;
2. MP infection was confirmed in nasopharyngeal secretions and serum samples using PCR and ELISA;
3. age between 6 months and 12 years;
4. disease duration less than 2 weeks;
5. written informed consent provided by the guardians.

Exclusion Criteria:

1. Previous history of wheezing;
2. Cardiovascular disease and congenital tracheal dysplasia;
3. pneumonia induced by other causes;
4. Dysplasia of bronchial and pulmonary tracts;
5. premature infants;
6. Combined with immunosuppressive diseases;
7. Presence of mental illness.